Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company will acquire ImCheck for €350m.
But Perspective sinks again.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
